8-Bromo-cGMP sodium 

8-Bromo-cGMP sodium, a membrane-permeable analogue of cGMP, is a PKG (protein kinase G) activator. 8-Bromo-cGMP sodium significantly inhibits Ca²⁺ macroscopic currents and impairs insulin release stimulated with high K^+[1]. 8-Bromo-cGMP sodium has antinociceptive effects and results in vasodilator responses^[2].

8-Bromo-cGMP sodium (1-100 μM; 8 h) increases resistance of LLC-PK1 cells to CsA toxicity concentration-dependently^[3].
8-Bromo-cGMP sodium (1-100 μM; 16 h) induces the synthesis of HO-1 protein in a concentration-dependent fashion^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

8-Bromo-cGMP sodium (0.3, 1, 3.0 nmol; intrathecal administration; 10 min before test) dose-dependently and significantly increases the tail-flick latency in Vincristine-treated mice to the level observed in vehicle-treated naive mice (male ICR mice, 4weeks of age and weighing 20 g). Vincristine (0.05 mg/kg 1 day after the pre-drug tail-flick latency, and then 0.125 mg/kg twice a week for 6 weeks) can induce painful neuropathy in mice^[4].
8-Bromo-cGMP sodium (10 mg/kg; iv; single dose) results in vasodilator responses in eNOS-Tg mice and WT littermates in C57BL/6 background (19-35 g)^[5].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

446.08

C₁₀H₁₀BrN₅NaO₇P

51116-01-9

固体

White to off-white

Room temperature in continental US; may vary elsewhere.

-20°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

• [1]. Sarkar O , et al. Nitric oxide attenuates overexpression of Giα proteins in vascular smooth muscle cells from SHR: Role of ROS and ROS-mediated signaling. PLoS One. 2017 Jul 10;12(7):e0179301.  [Content Brief]

  [2]. Tegeder I , et al. Dual effects of spinally delivered 8-bromo-cyclic guanosine mono-phosphate (8-bromo-cGMP) in formalin-induced nociception in rats. Neurosci Lett. 2002 Oct 31;332(2):146-50.  [Content Brief]

  [3]. Tobias Polte, et al. Atrial natriuretic peptide reduces cyclosporin toxicity in renal cells: role of cGMP and heme oxygenase-1. Free Radic Biol Med. 2002 Jan 1;32(1):56-63.  [Content Brief]

  [4]. Junzo Kamei, et al. Possible involvement of the spinal nitric oxide/cGMP pathway in vincristine-induced painful neuropathy in mice. Pain. 2005 Sep;117(1-2):112-20.  [Content Brief]

  [5]. Elza D van Deel, et al. Vasomotor control in mice overexpressing human endothelial nitric oxide synthase. Am J Physiol Heart Circ Physiol. 2007 Aug;293(2):H1144-53.  [Content Brief]